Jack A. Roth M.D., Key Medical & Scientific Advisor and SAB Chairman
Jack A. Roth M.D., an internationally-recognized pioneer in targeted therapies for cancer, is the lead inventor of Oncoprex and was principle investigator for the world’s first IND for gene therapy for lung cancer. Dr. Roth is Professor and Bud Johnson Clinical Distinguished Chair, Department of Thoracic and Cardiovascular Surgery; Professor of Molecular and Cellular Oncology; Director, W.M. Keck Center for Innovative Cancer Therapies; and Chief, Section of Thoracic Molecular Oncology, UTMDACC. Dr. Roth is the author of more than 600 peer-reviewed original research publications, the author of approximately 100 invited articles, the author of approximately 65 other articles and abstracts, the author of more than 100 book chapters and serves as editor or editorial board member of a number of medical journals. He has been an invited presenter at hundreds of medical and scientific conferences and symposia. Dr. Roth is the inventor of approximately 40 separate patent families representing hundreds of patents and patent applications. Most recently, he was selected as the 2015 Honorary Member of the American Society for Radiation Oncology (ASTRO), the highest honor ASTRO bestows on distinguished cancer researchers, scientists and leaders in disciplines other than radiation oncology, radiobiology or radiation physics.
Dr. Roth received his Bachelor of Arts degree from Cornell University in Ithaca, New York and received his MD degree from the Johns Hopkins University School of Medicine.